Truist raised the firm's price target on Harmony Biosciences to $29 from $25 and keeps a Hold rating on the shares after meeting with the company's management team. Wakix has a reasonable path to achieving FY26 guidance of over $1B, supported in part by the recent 20% expansion of the sales force, the analyst tells investors in a research note.
